TRIVAIR Trademark

Trademark Overview


On Wednesday, March 11, 2020, a trademark application was filed for TRIVAIR with the United States Patent and Trademark Office. The USPTO has given the TRIVAIR trademark a serial number of 88830833. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Wednesday, February 7, 2024. This trademark is owned by Acerus Biopharma Inc.. The TRIVAIR trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Inhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutica...

Medical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD
trivair

General Information


Serial Number88830833
Word MarkTRIVAIR
Filing DateWednesday, March 11, 2020
Status653 - SUSPENSION LETTER - MAILED
Status DateWednesday, February 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesInhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; inhalers filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; inhalers filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; inhalers filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; inhalers filled with pharmaceutical preparations for use in the treatment of cancer; inhalers filled with pharmaceutical preparations for use in the treatment of nausea; inhalers filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; inhalers filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of chronic pain; inhalers filled with pharmaceutical preparations for use in the treatment of insomnia; inhalers filled with pharmaceutical preparations for use in the relief of pain; inhalers filled with pharmaceutical preparations for use in the treatment of cough or sore throat; inhalers filled with pharmaceutical preparations for use in the treatment of candida infection; inhalers filled with pharmaceutical preparations for use in anti-fungal treatment; inhalers filled with pharmaceutical preparations for use in sedation; inhalers filled with pharmaceutical preparations for use in hormone replacement therapy; inhalers filled with pharmaceutical preparations for use in the treatment of psychosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of asthma; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of rhinitis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of sinus polyps; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of viral airway infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of depression; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of epilepsy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of migraine; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cancer; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of nausea; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of insomnia; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the relief of pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cough or sore throat; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of candida infection; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in anti-fungal treatment; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in sedation; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in hormone replacement therapy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of psychosis; inhalers used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; inhalers filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; none of the foregoing containing cannabis or CBD
Goods and ServicesMedical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 18, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, March 18, 2020
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAcerus Biopharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMississauga, Ontario L5L1J9
CA

Trademark Events


Event DateEvent Description
Wednesday, February 7, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, February 7, 2024LETTER OF SUSPENSION E-MAILED
Wednesday, February 7, 2024SUSPENSION LETTER WRITTEN
Friday, February 2, 2024ASSIGNED TO EXAMINER
Tuesday, January 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 30, 2024ASSIGNED TO LIE
Monday, May 15, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, November 15, 2022NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, November 15, 2022INQUIRY TO SUSPENSION E-MAILED
Tuesday, November 15, 2022SUSPENSION INQUIRY WRITTEN
Friday, October 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 28, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, October 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, May 18, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, May 18, 2022LETTER OF SUSPENSION E-MAILED
Wednesday, May 18, 2022SUSPENSION LETTER WRITTEN
Wednesday, May 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 11, 2022ASSIGNED TO LIE
Tuesday, May 10, 2022NOTICE OF REVIVAL - E-MAILED
Monday, May 9, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 9, 2022PETITION TO REVIVE-GRANTED
Monday, May 9, 2022TEAS PETITION TO REVIVE RECEIVED
Tuesday, May 3, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, May 3, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Tuesday, May 3, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, May 3, 2022ASSIGNED TO EXAMINER
Tuesday, October 5, 2021NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, October 5, 2021INQUIRY TO SUSPENSION E-MAILED
Tuesday, October 5, 2021SUSPENSION INQUIRY WRITTEN
Wednesday, September 1, 2021SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, January 8, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, January 8, 2021LETTER OF SUSPENSION E-MAILED
Friday, January 8, 2021SUSPENSION LETTER WRITTEN
Tuesday, January 5, 2021EXAMINER'S AMENDMENT ENTERED
Tuesday, January 5, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, January 5, 2021EXAMINERS AMENDMENT E-MAILED
Tuesday, January 5, 2021EXAMINERS AMENDMENT -WRITTEN
Monday, September 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, September 14, 2020NON-FINAL ACTION E-MAILED
Monday, September 14, 2020NON-FINAL ACTION WRITTEN
Monday, September 14, 2020ASSIGNED TO EXAMINER
Wednesday, June 17, 2020ASSIGNED TO EXAMINER
Tuesday, June 2, 2020ASSIGNED TO EXAMINER
Wednesday, March 18, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 14, 2020NEW APPLICATION ENTERED